WO2012105798A3 - 클로로겐산을 포함하는 위식도 역류 질환의 예방 또는 치료용 조성물 - Google Patents

클로로겐산을 포함하는 위식도 역류 질환의 예방 또는 치료용 조성물 Download PDF

Info

Publication number
WO2012105798A3
WO2012105798A3 PCT/KR2012/000746 KR2012000746W WO2012105798A3 WO 2012105798 A3 WO2012105798 A3 WO 2012105798A3 KR 2012000746 W KR2012000746 W KR 2012000746W WO 2012105798 A3 WO2012105798 A3 WO 2012105798A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
chlorogenic acid
treating gastroesophageal
reflux disease
gastroesophageal reflux
Prior art date
Application number
PCT/KR2012/000746
Other languages
English (en)
French (fr)
Other versions
WO2012105798A2 (ko
Inventor
이선미
강정우
Original Assignee
성균관대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 성균관대학교 산학협력단 filed Critical 성균관대학교 산학협력단
Publication of WO2012105798A2 publication Critical patent/WO2012105798A2/ko
Publication of WO2012105798A3 publication Critical patent/WO2012105798A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 클로로겐산(chlorogenic acid), 이의 약학적으로 허용가능한 염, 또는 이의 유도체를 포함하는, 위식도 역류 질환의 예방 또는 치료용 약학적 조성 물 및 위식도 역류 질환의 예방 또는 개선용 식품 조성물, 상기 약학적 조성물을 개체에 투여하는 단계를 포함하는 위식도 역류 질환을 예방 또는 치료하는 방법, 및 클로로겐산, 이의 약학적으로 허용가능한 염, 또는 이의 유도체의 용도에 관한 것이다. 본 발명에 따르면, 클로로겐산, 이의 약학적으로 허용가능한 염, 또는 이의 유도체는 위 내 pH 변화 없이, 위 또는 십이지장의 내용물이 식도로 역류하여 발생되는 식도 병변의 면적을 감소시키고, 염증 세포의 조직학적 변화를 감소시키는 바, 부작용 없이 위식도 염류성 질환의 예방 또는 치료에 유용하게 사용될 수 있다.
PCT/KR2012/000746 2011-01-31 2012-01-31 클로로겐산을 포함하는 위식도 역류 질환의 예방 또는 치료용 조성물 WO2012105798A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110009729 2011-01-31
KR10-2011-0009729 2011-01-31

Publications (2)

Publication Number Publication Date
WO2012105798A2 WO2012105798A2 (ko) 2012-08-09
WO2012105798A3 true WO2012105798A3 (ko) 2012-12-20

Family

ID=46603207

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/000746 WO2012105798A2 (ko) 2011-01-31 2012-01-31 클로로겐산을 포함하는 위식도 역류 질환의 예방 또는 치료용 조성물

Country Status (2)

Country Link
KR (1) KR101420347B1 (ko)
WO (1) WO2012105798A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101074839B1 (ko) * 2010-11-25 2011-10-19 주식회사 녹십자 금은화 추출물을 포함하는 역류성 식도염 치료 또는 예방용 약학조성물
JP6290896B2 (ja) * 2012-09-21 2018-03-07 ネステク ソシエテ アノニム 植物性フェノール、及び好酸球性食道炎の治療若しくは予防におけるその使用
KR102332846B1 (ko) * 2019-09-06 2021-11-30 고려대학교 산학협력단 과식에 의해 유도된 위식도역류질환 동물모델의 제조방법
WO2023115051A1 (en) * 2021-12-17 2023-06-22 Cargill, Incorporated Sensory modifiers for reduced sugar cocoa compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100878436B1 (ko) * 2008-08-18 2009-01-13 주식회사 지씨에이치앤피 금은화 추출물을 포함하는 소화성 궤양 치료 또는 예방용 약학조성물
KR20100043882A (ko) * 2008-10-21 2010-04-29 김정환 헬리코박터 파이로리 균에 항균능을 갖는 뽕잎추출물, 이의제조방법 및 이를 이용한 건강기능식품
WO2010083968A1 (en) * 2009-01-20 2010-07-29 Indena S.P.A. Compositions comprising a lipophilic extract of zingiber officinale and an extract of cynara scolymus, which are useful for the prevention and treatment of oesophageal reflux and irritable bowel syndrome
KR101074839B1 (ko) * 2010-11-25 2011-10-19 주식회사 녹십자 금은화 추출물을 포함하는 역류성 식도염 치료 또는 예방용 약학조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100878436B1 (ko) * 2008-08-18 2009-01-13 주식회사 지씨에이치앤피 금은화 추출물을 포함하는 소화성 궤양 치료 또는 예방용 약학조성물
KR20100043882A (ko) * 2008-10-21 2010-04-29 김정환 헬리코박터 파이로리 균에 항균능을 갖는 뽕잎추출물, 이의제조방법 및 이를 이용한 건강기능식품
WO2010083968A1 (en) * 2009-01-20 2010-07-29 Indena S.P.A. Compositions comprising a lipophilic extract of zingiber officinale and an extract of cynara scolymus, which are useful for the prevention and treatment of oesophageal reflux and irritable bowel syndrome
KR101074839B1 (ko) * 2010-11-25 2011-10-19 주식회사 녹십자 금은화 추출물을 포함하는 역류성 식도염 치료 또는 예방용 약학조성물

Also Published As

Publication number Publication date
KR20120088610A (ko) 2012-08-08
KR101420347B1 (ko) 2014-07-16
WO2012105798A2 (ko) 2012-08-09

Similar Documents

Publication Publication Date Title
WO2012031124A3 (en) Drug formulations using water soluble antioxidants
EA201792541A3 (ru) Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
WO2013052699A3 (en) Novel quinoxaline inhibitors of pi3k
MX2010010647A (es) Proceso para preparar formulaciones de dabigatran para administracion oral.
WO2009062118A3 (en) Modulation of protein trafficking
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
PL2763982T3 (pl) Podstawione benzyloindazole do zastosowania jako inhibitory kinazy Bub1 w leczeniu chorób hiperproliferacyjnych
WO2012106303A1 (en) Pharmaceutical formulations including an amine compound
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2011056021A3 (ko) 벤조헤테로사이클 유도체의 암 예방 및 치료 또는 암 전이 억제를 위한 용도
WO2009139576A3 (ko) 신규 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 이상세포 성장 질환의 예방 및 치료용 약학적 조성물
WO2012105798A3 (ko) 클로로겐산을 포함하는 위식도 역류 질환의 예방 또는 치료용 조성물
WO2012071369A3 (en) A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
IL266097A (en) Citric acid acid salt of (R)-5-((E)-2-(pyrrolidine-3-yl)vinyl)pyrimidine, a pharmaceutical preparation containing the salt, use of the salt in the production of a medicine, salt for use, and method of production
JP2016534081A5 (ja) ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
DK2268605T3 (da) Fedtsyrederivater til oral indgivelse forsynet med høj palatabilitet
EP2796450A4 (en) 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES
MX339829B (es) Metodo para estabilizar daño de articulacion en sujetos utilizando inhibidores de xantina oxidoreductasa.
WO2010114425A8 (ru) Фармацевтическая композиция ингибитора протонной помпы и пребиотика для лечения язвенных поражений желудка и 12- перстной кишки
WO2010022201A3 (en) Folinic acid derivatives for promoting bone growth
WO2012064396A3 (en) Novel ezrin inhibitors and methods of making and using
WO2007095117A3 (en) Method for improving the oral administration of alpha-lipoic acid
WO2012085249A3 (en) Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12742368

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12742368

Country of ref document: EP

Kind code of ref document: A2